Drug Giant Faced a Reckoning as China Took Aim at Bribery

David Barboza
New York Times
China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties

GSK China’s Private-Eyes Indicted in Shanghai for Illegal Probe

Xinhua
Peter William Humphrey, a 58-year-old Brit, and his wife Yu Ying Zeng, a 61-year old American, were arrested last August. Theirs is the first indictment Chinese prosecutors have announced on foreigners for illegal investigation.

Undercover Sex Tape Deepens GSK’s China Scandal

Harriet Dennys
Telegraph
GlaxoSmithKline has confirmed the existence of a sex tape featuring Mark Reilly, the former manager at the centre of the company's corruption investigation...

Chinese Police Charge British Former Head of GSK in China With Bribery

Megha Rajagopalan and Kazunori Takada
Reuters
The case is the biggest corruption scandal to hit a foreign company in China since the Rio Tinto affair in 2009, which resulted in four executives, including an Australian, being jailed for between 7-14 years.

Bribery in G.S.K. China Was Coordinated at Company Level

Reuters
A Chinese police investigation into drugmaker GlaxoSmithKline has discovered that alleged bribery of doctors in China was coordinated by the British company and was not the work of individual employees, state...

Corporate Sleuths On Edge After China Detains Foreign Consultants

Alexandra Harney
Reuters
The detention by Chinese authorities of a British corporate investigator and his American wife in the wake of a corruption probe into pharmaceutical giant GlaxoSmithKline has had a chilling effect on other risk consultants working...

Conversation

07.30.13

Is Business in China Getting Riskier, Or Are Multinationals Taking More Risks?

Arthur R. Kroeber, David Schlesinger & more
Arthur Kroeber:The environment for foreign companies in China has been getting steadily tougher since 2006, when the nation came to the end of a five-year schedule of market-opening measures it pledged as the price of admission to the World Trade...

Glaxo Chief Executive Addresses China Inquiry

Katie Thomas
New York Times
Andrew Witty, chief executive of the drug maker GlaxoSmithKline, said on Wednesday that the accusations of bribery and corruption against his company in China were “deeply disappointing.” But he said that Glaxo’s headquarters in London had not been...

More Foreign Pharmaceutical Firms Could Be Probed In China

Michael Martina
Reuters
China's official news agency hinted that more foreign pharmaceutical firms could soon be implicated in a corruption scandal sweeping the industry, in the wake of bribery accusations against British drug maker GlaxoSmithKline. ...

Drug Research in China Falls Under a Cloud

Katie Thomas
New York Times
A leaked document related to the recent G.S.K. scandal underscores the problems that can arise when major drug companies export their scientific development to emerging markets like China. 

Glaxo Says Executives May Have Broken Chinese Law

David Barboza
New York Times
The British pharmaceutical giant GlaxoSmithKline said Monday that some of its executives might have broken the law in China, the company’s strongest statement yet on a bribery and corruption scandal that has engulfed its China...

China Bars GlaxoSmithKline Executive From Leaving During a Bribery Inquiry

David Barboza
New York Times
The effort to restrict Steve Nechelput’s travel came as the government ramped up an unusually bold anti-corruption campaign against GlaxoSmithKline, which is one of the world’s biggest drug makers.